Navigation Links
ICON Selected to Manage Lilly Clinical Trial Site Set Up and Monitoring in Europe
Date:6/9/2009

DUBLIN, June 9 /PRNewswire-FirstCall/ -- ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has signed a strategic partnership with Eli Lilly and Company (NYSE: LLY) to manage the company's clinical trial site set up and monitoring in Europe for Lilly managed studies. The agreement, which is subject to the relevant employee consultation processes, is a continuation of Lilly's ongoing transformation of its research and development organisation and follows Lilly's selection of ICON to manage its clinical data management business outside of the US, which was announced in November 2008.

"Today's announcement marks another milestone in the successful partnership between ICON and Lilly," commented Peter Gray, CEO at ICON. "We have worked together to create a truly flexible model that better meets Lilly's patient and portfolio needs and will also drive productivity within Lilly's clinical operations in Europe. We look forward to continuing to assist Lilly with its transformation initiatives and to delivering the quality services that will expedite their drug development pipelines."

"We are constantly evaluating how we can do things better to increase our flexibility and focus our internal efforts on our core capabilities," commented Jeff Kasher, Lilly Vice President and Chief Operating Officer of Global Clinical Development." This strategic agreement enables us to leverage ICON's significant expertise in clinical trial monitoring and site management in Europe and will increase our ability to speed innovative medicines to patients."

About ICON plc

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has over 7,100 employees, operating from 71 locations in 38 countries.

Further information is available at http://www.iconplc.com

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

    ICON/ICLR-G

    US contact:
    Courtney Judd
    +1-212-445-8365
    cjudd@webershandwick.com

    UK contact:
    Erika Aalto
    +44(0)20-706-70-214
    eaalto@webershandwick.com



'/>"/>
SOURCE ICON plc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Brooke Franchise Corporation Announces Selected July Results
2. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
3. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
4. Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services
5. Fry Construction Selected for High-Profile Medical Imaging Project
6. Meth Project Advertisements Selected for National Prevention Campaign
7. Eight Graduate Nursing Students Selected to Receive The California Endowment-AACN Minority Nurse Faculty Scholarship
8. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
9. SAIC Selected to Support the U.S. Military Theater Medical Information Program-Joint
10. The Cooper Institutes FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool
11. CBaySystems Selected to Receive Deloittes 2007 Maryland Technology Fast 50 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm ... its corporate headquarters to a new, more expansive office space in order to ... Qualidigm purchased a distressed office building in Wethersfield, Conn. located at 936 Silas ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... work, the Self-Funding Success website has recently developed and published an informational resource ... ” was created based on common inquiries the site’s team of third party ...
(Date:3/28/2017)... ... March 28, 2017 , ... AutismOne announced the Board Certified ... Integrative Medicine and available for application on Saturday, May 27, 2017, following Thursday, ... Colorado Springs. , Ed Arranga, president of AutismOne, stated: "Many of the modalities ...
(Date:3/28/2017)... ... ... With expansion and efficiency in mind, Patten Seed Company completed relocation of its ... in Marshallville in 2006, and a bagging and shipping facility has been in place ... Seed operations to the Middle Georgia location from their previous home in Lakeland, Georgia. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Nurse practitioners and ... their value increases in the healthcare workforce, according to a survey recently released ... career fairs, and candidate leads to healthcare employers of physicians and advanced practice ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... The global market for mass ... top three companies, namely Shimadzu Corporation, Thermo Fisher Scientific, ... of the overall market in 2015, observes Transparency Market ... intensely competitive and has few players, most of them ... have restricted the entry of new players in the ...
(Date:3/28/2017)... Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today ... Christopher Gabrieli , partner emeritus ... of the board of Akcea Therapeutics. ... Sandford D. Smith , founder and ... are excited to announce this expansion to our board and ...
(Date:3/28/2017)... 2017 The global surgical ... value of USD 4.5 billion by 2025, according to ... closure of injured tissues post operation is a major ... occur in 3% to 15% of cases and are ... one third of postoperative deaths in patients. Surgical sealants ...
Breaking Medicine Technology: